108 related articles for article (PubMed ID: 15739019)
21. Cathepsin D, both a prognostic factor and a predictive factor for the effect of adjuvant tamoxifen in breast cancer. South Sweden Breast Cancer Group.
Fernö M; Baldetorp B; Borg A; Brouillet JP; Olsson H; Rochefort H; Sellberg G; Sigurdsson H; Killander D
Eur J Cancer; 1994; 30A(14):2042-8. PubMed ID: 7857700
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic values of serum cathepsin B and D in patients with nasopharyngeal carcinoma.
Tan G; Liu Q; Tang X; Kang T; Li Y; Lu J; Zhao X; Tang F
BMC Cancer; 2016 Mar; 16():241. PubMed ID: 26995190
[TBL] [Abstract][Full Text] [Related]
23. PS2 in breast cancer--alternative or complementary tool to steroid receptor status? Evaluation of 446 cases.
Gion M; Mione R; Pappagallo GL; Gatti C; Nascimben O; Bari M; Leon AE; Vinante O; Bruscagnin G
Br J Cancer; 1993 Aug; 68(2):374-9. PubMed ID: 8347494
[TBL] [Abstract][Full Text] [Related]
24. Prognostic and predictive value of cathepsin X in serum from colorectal cancer patients.
Vižin T; Christensen IJ; Wilhelmsen M; Nielsen HJ; Kos J
BMC Cancer; 2014 Apr; 14():259. PubMed ID: 24725597
[TBL] [Abstract][Full Text] [Related]
25. Prognostic value of PS2 and cathepsin D in 710 human primary breast tumors: multivariate analysis.
Foekens JA; van Putten WL; Portengen H; de Koning HY; Thirion B; Alexieva-Figusch J; Klijn JG
J Clin Oncol; 1993 May; 11(5):899-908. PubMed ID: 8487052
[TBL] [Abstract][Full Text] [Related]
26. Cathepsin D may help in discriminating node-negative breast cancer patients at risk for local-regional recurrence.
Ardavanis A; Scorilas A; Loukeri A; Gerakini F; Pissakas G; Missitzis I; Apostolikas N; Yiotis I
Anticancer Res; 1998; 18(4B):2885-90. PubMed ID: 9713481
[TBL] [Abstract][Full Text] [Related]
27. [The prognostic significance of cathepsin D in primary breast cancer].
Crombach G; Ingenhorst A; Göhring UJ; Scharl A; Schaeffer HJ; Stützer H; Bolte A
Geburtshilfe Frauenheilkd; 1994 Oct; 54(10):545-51. PubMed ID: 8001750
[TBL] [Abstract][Full Text] [Related]
28. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients.
Korkolis DP; Tsoli E; Fouskakis D; Yiotis J; Koullias GJ; Giannopoulos D; Papalambros E; Nikiteas NI; Spiliopoulou CA; Patsouris E; Asimacopoulos P; Gorgoulis VG
Anticancer Res; 2004; 24(3b):2061-8. PubMed ID: 15274401
[TBL] [Abstract][Full Text] [Related]
29. Predictive value of CD44 and CD24 for prognosis and chemotherapy response in invasive breast ductal carcinoma.
Chen Y; Song J; Jiang Y; Yu C; Ma Z
Int J Clin Exp Pathol; 2015; 8(9):11287-95. PubMed ID: 26617852
[TBL] [Abstract][Full Text] [Related]
30. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).
Harbeck N; Kates RE; Look MP; Meijer-Van Gelder ME; Klijn JG; Krüger A; Kiechle M; Jänicke F; Schmitt M; Foekens JA
Cancer Res; 2002 Aug; 62(16):4617-22. PubMed ID: 12183417
[TBL] [Abstract][Full Text] [Related]
31. The role of cathepsin D and PAI-1 in primary invasive breast cancer as prognosticators and predictors of treatment benefit with adjuvant tamoxifen.
Billgren AM; Rutqvist LE; Johansson H; Hägerström T; Skoog L
Eur J Cancer; 2000 Jul; 36(11):1374-80. PubMed ID: 10899650
[TBL] [Abstract][Full Text] [Related]
32. Prognostic value of cathepsin D in breast cancer: comparison of immunohistochemical and immunoradiometric detection methods.
Göhring UJ; Scharl A; Thelen U; Ahr A; Crombach G; Titius BR
J Clin Pathol; 1996 Jan; 49(1):57-64. PubMed ID: 8666688
[TBL] [Abstract][Full Text] [Related]
33. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
[TBL] [Abstract][Full Text] [Related]
34. Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status.
Diel IJ; Kaufmann M; Costa SD; Holle R; von Minckwitz G; Solomayer EF; Kaul S; Bastert G
J Natl Cancer Inst; 1996 Nov; 88(22):1652-8. PubMed ID: 8931609
[TBL] [Abstract][Full Text] [Related]
35. Flow cytometric DNA analysis and lysosomal cathepsins B and L in locally advanced laryngeal cancer. Relationship with clinicopathologic parameters and prognostic significance.
Russo A; Bazan V; Gebbia N; Pizzolanti G; Tumminello FM; Dardanoni G; Ingria F; Restivo S; Tomasino RM; Leto G
Cancer; 1995 Nov; 76(10):1757-64. PubMed ID: 8625044
[TBL] [Abstract][Full Text] [Related]
36. [The prognostic value of cathepsin D concentration in cytosol of primary breast carcinoma].
Bussen S; Rempen A; Caffier H
Zentralbl Gynakol; 1995; 117(5):253-9. PubMed ID: 7793167
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
38. A prospective study of the prognostic value of cathepsin D levels in breast cancer cytosol.
Pujol P; Maudelonde T; Daures JP; Rouanet P; Brouillet JP; Pujol H; Rochefort H
Cancer; 1993 Mar; 71(6):2006-12. PubMed ID: 8443752
[TBL] [Abstract][Full Text] [Related]
39. Prognostic impact of tumor biological factors on survival in node-negative breast cancer.
Harbeck N; Dettmar P; Thomssen C; Henselmann B; Kuhn W; Ulm K; Jänicke F; Höfler H; Graeff H; Schmitt M
Anticancer Res; 1998; 18(3C):2187-97. PubMed ID: 9703782
[TBL] [Abstract][Full Text] [Related]
40. Prognostic value of the urokinase-type plasminogen activator, and its inhibitors and receptor in breast cancer patients.
Borstnar S; Vrhovec I; Svetic B; Cufer T
Clin Breast Cancer; 2002 Jun; 3(2):138-46. PubMed ID: 12123538
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
